Odyssey Health, Inc. — fact timeline

Odyssey Health, Inc. amended Amendment No. 12 with LGH Investments, LLC (effective 2026-04-30).

“On May 18, 2026, Odyssey Health, Inc., entered into Amendment No. 12 with LGH Investments, LLC, effective as of April 30, 2026.”

Odyssey Health, Inc. amended debt with LGH Investments, LLC maturing September 30, 2026.

“the parties have agreed to extend the maturity date of the note to September 30, 2026. All other terms and conditions remain the same”

Odyssey Health, Inc. entered into Master Technology and Sub-license Agreement with NeuRX Health, Inc. (effective 2025-10-14).

“On April 21, 2026, Odyssey Health, Inc., a Nevada corporation (“ Odyssey ” the “ Company ”) successfully closed the Master Technology and Sub-license Agreement (the “ Agreement ”) with NeuRX Health, Inc. (“ NeuRX ”) which was entered into on October 14, 2025”

Odyssey Health, Inc. issued 1,538,461 shares of the Company's common stock of warrant to Mast Hill Fund, L.P..

“the Company issued Warrants to MHF immediately exercisable for 1,538,461 shares of the Company's common stock at $0.001 per share”

Odyssey Health, Inc. issued convertible note to Mast Hill Fund, L.P. for up to $25,000,000.

“the Company issued to MHF a convertible promissory note in the original principal amount of $2,262,000”

Odyssey Health, Inc. incurred convertible notes of up to $25,000,000 with Mast Hill Fund, L.P. at OID of 10% on each tranche.

“the Company may issue a promissory note with a maximum principal amount of up to $25,000,000 in multiple tranches”

Odyssey Health, Inc. incurred convertible notes of $2,262,000 with Mast Hill Fund, L.P. at 10% per annum maturing November 13, 2026.

“the Company issued to MHF a convertible promissory note in the original principal amount of $2,262,000 which bears interest at 10% per annum and is due November 13, 2026”

Odyssey Health, Inc. amended loan with Mast Hill Fund, L.P. maturing April 30, 2026.

“On October 9, 2025, Odyssey Health, Inc. entered into Amendment No. 6 to the Promissory Note issued on December 13, 2022, with Mast Hill Fund, L.P. Pursuant to Amendment No. 6, the parties have agreed to extend the maturity date of the note to April 30, 2026”

Odyssey Health, Inc. incurred loan of $100,000 with Peter D'Arruda at 18% per annum maturing one-year.

“On October 3, 2025, Odyssey Health, Inc., (the "Company" or "Odyssey"), received one hundred thousand dollars ($100,000) related to a Promissory Note Agreement (the "Note") with Peter D'Arruda, an accredited private investor, that was entered into by all parties on October 3, 2025 and effective as of October 1, 2025.”

Odyssey Health, Inc. amended debt with LGH Investments, LLC maturing January 31, 2026.

“On September 18, 2025, Odyssey Health, Inc., entered into Amendment No. 10 with LGH Investments, LLC, effective as of July 31, 2025. Pursuant to Amendment No. 10, the parties have agreed to extend the maturity date of the note to January 31, 2026.”

Odyssey Health, Inc. amended debt with two directors and two officers of the Company maturing January 31, 2026.

“the parties have agreed to extend the maturity date of the note to January 31, 2026.”

Odyssey Health, Inc. amended loan with Mast Hill Fund, L.P. maturing October 10, 2025.

“On July 11, 2025, the Company entered into Amendment No. 5 to the Promissory Note issued on December 13, 2022, with Mast Hill Fund, L.P. Pursuant to the Amendment No. 5, the parties have agreed to extend the maturity date of the note to October 10, 2025.”

Odyssey Health, Inc. amended convertible notes with LGH Investments, LLC maturing July 31, 2025.

“On February 19, 2025, effective December 31, 2024, the Company entered into Amendment No. 9 to the Convertible Promissory Note to the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC. Pursuant to the Amendment No. 9, the parties have agreed to extend the maturity date of the note to July 31, 2025.”

Odyssey Health, Inc. amended loan with Jon Lutz maturing July 31, 2025.

“On February 13, 2025, the Company entered into Amendment No. 3 to the Promissory Note; dated February 13, 2024 with Jon Lutz, an accredited investor. Pursuant to the Amendment No 3, the parties have agreed to extend the maturity date of the note to July 31, 2025.”

Odyssey Health, Inc. amended loan of the principal of the promissory notes remains the same with directors and officers of the Company at the interest rate of the promissory notes remains the same maturing the maturity date of the note was extended to July 31, 2025.

“On January 31, 2025, Odyssey Health, Inc., entered into four Promissory Note Amendments (the "Amendments"), to the Promissory Notes entered into December 21, 2021 and December 22, 2021 and as amended April 20, 2022, June 3, 2022, September 30, 2022, December 30, 2022, March 31, 2023, June 30, 2023, November 1, 2023, January 31, 2024, and July 31, 2024 with two directors and two officers of the Company. Pursuant to the Amendments, the parties have agreed to extend the maturity date of the note to July 31, 2025. All other terms and conditions remain the same.”

Odyssey Health, Inc. amended convertible notes of sixty thousand ($60,000) with LGH Investments, LLC maturing June 30, 2024.

“On December 30, 2023, the Company entered into Amendment No. 7 to the Convertible Promissory Note (the “Amendment”) to the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC (“LGH”). Pursuant to the Amendment, the parties have agreed to extend the maturity date of the note to June 30, 2024. As consideration, sixty thousand ($60,000) shall be added to the principal amount outstanding.”

Odyssey Health, Inc. amended Amendment No. 7 to the Convertible Promissory Note with LGH Investments, LLC valued at $60,000 (effective 2023-12-30).

“On December 30, 2023, the Company entered into Amendment No. 7 to the Convertible Promissory Note (the “Amendment”) to the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC (“LGH”). Pursuant to the Amendment, the parties have agreed to extend the maturity date of the note to June 30, 2024. As consideration, sixty thousand ($60,000) shall be added to the principal amount outstanding.”

Odyssey Health, Inc. completed a disposition involving Oragenics, Inc. for $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock (closed 2023-12-28).

“to a segment of Odyssey’s business focused on developing medical products that treat brain related illnesses and diseases (the “ Purchased Assets ”) to Oragenics in exchange for $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock (“ Series F Preferred Stock ”), on and subject to the terms and conditions set forth therein”

Odyssey Health, Inc. shareholders approved Approval of adjournment or postponement of the Special Meeting, if necessary at the 2023-12-07 meeting.

“(2) approved the adjournment or postponement of the Special Meeting, if necessary.”

Odyssey Health, Inc. shareholders approved Approval of the asset purchase agreement of its neurological drug therapies and technologies to Oragenics, Inc. (reported as Oragenics in context? Actually the text says "Odyssey Health, Inc. formerly known as Odyssey Group International, Inc. (“Odyssey”) held its Special Meeting of Stockholders. At at the 2023-12-07 meeting.

“(1) approved the asset purchase agreement of its neurological drug therapies and technologies to Oragenics, Inc.;”

Odyssey Health, Inc. amended loan with two directors and two officers of the Company maturing January 31, 2024.

“On November 1, 2023, Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (the “Company”), entered into four Promissory Note Amendments (the “Amendments”), to the Promissory Notes entered into December 21, 2021 and December 22, 2021 and as amended April 20, 2022, June 3, 2022, September 30, 2022, December 30, 2022, March 31, 2023 and June 30, 2023, with two directors and two officers of the Company. Pursuant to the Amendments, the parties have agreed to extend the maturity date of the note to January 31, 2024.”

John Gandolfo resigned as director at Odyssey Health, Inc..

“Effective October 5, 2023, John Gandolfo resigned as a director of Odyssey Health, Inc.”

Odyssey Health, Inc. entered into Asset Purchase Agreement with Oragenics, Inc. valued at $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock (effective 2023-10-04).

“On October 4, 2023, Odyssey Health, Inc. (f/k/a Odyssey Group International, Inc., a Nevada corporation (“ Odyssey ” the “ Company ”) entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) with Oragenics, Inc. (“ Oragenics ” the “ Purchaser ”).”

Odyssey Health, Inc. incurred convertible notes of five hundred thousand ($500,000) with two accredited investors at 12% per annum maturing the later of twelve (12) months from execution or completion of a Senior Exchange Listing of the Company or a Company Spinout ("Spinco") of its ONP Technology.

“desires to issue and sell, as set forth in the NPA (i) a Convertible Promissory Note of the Company, (the “Note”), in aggregate principal amount of five hundred thousand ($500,000), (the “Loan Amount”), (ii) due and payable in full on or after the later of twelve (12) months from execution or completion of a Senior Exchange Listing of the Company or a”

Odyssey Health, Inc. entered into Note Purchase Agreement with two accredited investors valued at aggregate principal amount of five hundred thousand ($500,000) (effective 2023-08-15).

“On August 15, 2023, Odyssey Health, Inc., f/k/a Odyssey Group International, Inc. (the “Company”) entered into a Note Purchase Agreement (the “NPA”) with two accredited investors.”

Odyssey Health, Inc. amended convertible notes of $25,000 with LGH Investments, LLC at eight percent (8%) per annum maturing December 31, 2023.

“On July 6, 2023, the Company entered into Amendment No. 6 to the Convertible Promissory Note (the “Amendment”) to the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC (“LGH”). Pursuant to the Amendment, the parties have agreed to extend the maturity date of the note to December 31, 2023. As consideration, twenty five thousand ($25,000) shall be added to the principal amount outstanding, the interest rate of eight percent (8%) per annum shall be charged on the unpaid principal amount from the effective date and the conversion price shall be twelve cents ($0.12) per share.”

Odyssey Health, Inc. amended convertible notes with three directors and two officers of the Company maturing October 31, 2023.

“On June 30, 2023, Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (the “Company”), entered into five Promissory Note Amendments (the “Amendments”), to the Promissory Notes entered into December 21, 2021 and December 22, 2021 and as amended April 20, 2022, June 3, 2022 and September 30, 2022, December 30, 2023 and March 31, 2023 with three directors and two officers of the Company. Pursuant to the Amendments, the parties have agreed to extend the maturity date of the note to October 31, 2023 and the lender may convert the note prior to maturity at a conversion price of $0.12 per share.”

Odyssey Health, Inc. amended Amendment No. 6 to the Convertible Promissory Note with LGH Investments, LLC valued at Extended maturity date to December 31, 2023; added $25,000 to principal; 8% interest; conversion pri (effective 2023-07-06).

“On July 6, 2023, the Company entered into Amendment No. 6 to the Convertible Promissory Note (the “Amendment”) to the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC (“LGH”). Pursuant to the Amendment, the parties have agreed to extend the maturity date of the note to December 31, 2023. As consideration, twenty five thousand ($25,000) shall be added to the principal amount outstanding, the interest rate of eight percent (8%) per annum shall be charged on the unpaid principal amount from the effective date and the conversion price shall be twelve cents ($0.12) per share. All other terms and conditions remain the same.”

Odyssey Health, Inc. amended Promissory Note Amendments with three directors and two officers valued at Extended maturity date to October 31, 2023; conversion price $0.12 per share (effective 2023-06-30).

“On June 30, 2023, Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (the “Company”), entered into five Promissory Note Amendments (the “Amendments”), to the Promissory Notes entered into December 21, 2021 and December 22, 2021 and as amended April 20, 2022, June 3, 2022 and September 30, 2022, December 30, 2023 and March 31, 2023 with three directors and two officers of the Company. Pursuant to the Amendments, the parties have agreed to extend the maturity date of the note to October 31, 2023 and the lender may convert the note prior to maturity at a conversion price of $0.12 per share. All other terms and conditions remain the same.”

Odyssey Health, Inc. amended Amendment No. 5 to the Convertible Promissory Note with LGH Investments, LLC valued at $20,000 (effective 2023-03-31).

“On March 31, 2023, Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (the “Company”), entered into Amendment No. 5 to the Convertible Promissory Note (the “Amendment”) to the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC (“LGH”). Pursuant to the Amendment, the parties have agreed to extend the maturity date of the note to June 30, 2023. As consideration, twenty thousand ($20,000) shall be added to the principal amount outstanding.”

Odyssey Health, Inc. shareholders approved Ratify Turner Stone & Company LLP as Auditors at the 2023-01-12 meeting.

“Proposal #4: Ratify Turner Stone & Company LLP as Auditors Shares Voted For Shares Voted Against Shares Abstaining 43,960,197 57,968 99,514”

Odyssey Health, Inc. shareholders approved To Effect a Reverse Stock Split of Outstanding Common Stock at the 2023-01-12 meeting.

“Proposal #3: To Effect a Reverse Stock Split of Outstanding Common Stock Shares Voted For Shares Voted Against Shares Abstaining 39,772,694 4,305,977 39,008”

Odyssey Health, Inc. shareholders approved To Approve on an Advisory Basis Executive Compensation at the 2023-01-12 meeting.

“Proposal #2: To Approve on an Advisory Basis Executive Compensation Shares Voted For Shares Voted Against Shares Abstaining Broker Nonvotes 34,584,104 3,353,050 466,631 5,713,894”

Odyssey Health, Inc. shareholders approved Election of Directors at the 2023-01-12 meeting.

“Proposal #1: Election of Directors Nominee Shares Voted For Shares Voted to Withhold Authority Joseph M. Redmond 38,279,621 124,164 Jerome H. Casey 38,247,621 156,164 Jeffrey Conroy* 38,243,021 160,764 John P. Gandolfo 38,243,021 160,764 Ricky W. Richardson 38,280,671 123,114”

Jeffrey Conroy resigned as Director at Odyssey Health, Inc..

“Effective January 4, 2023, Jeffrey Conroy resigned as a director of Odyssey Health, Inc.”

Odyssey Health, Inc. amended loan with Jonathan Lutz maturing January 31, 2023.

“On December 30, 2022, the Company entered into a Promissory Note Amendment (the "Investor Amendment"), to the Promissory Notes entered into September 21, 2022, with Jonathan Lutz, an accredited investor. Pursuant to the Investor Amendment, the parties have agreed to extend the maturity date of the note to January 31, 2023.”

Odyssey Health, Inc. amended loan with three directors and two officers of the Company maturing March 31, 2023.

“On December 30, 2022, the Company entered into five Promissory Note Amendments (the "Amendments"), to the Promissory Notes entered into December 21, 2021 and December 22, 2021 and as amended April 20, 2022, June 3, 2022 and September 30, 2022, with three directors and two officers of the Company. Pursuant to the Amendments, the parties have agreed to extend the maturity date of the note to March 31, 2023.”

Odyssey Health, Inc. amended convertible notes of paydown thirty-five thousand ($35,000) towards the principal amount outstanding and fifty thousand ($50,000) shall be ad with LGH Investments, LLC maturing March 31, 2023.

“On December 29, 2022, Odyssey Health, Inc., f/k/a Odyssey Group International, Inc. (the "Company"), entered into Amendment No. 4 to the Convertible Promissory Note (the "Amendment") to the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC ("LGH"). Pursuant to the Amendment, the parties have agreed to extend the maturity date of the note to March 31, 2023. As consideration, the Company shall paydown thirty-five thousand ($35,000) towards the principal amount outstanding and fifty thousand ($50,000) shall be added to the principal amount outstanding.”

Odyssey Health, Inc. amended Promissory Note Amendment with Jonathan Lutz, an accredited investor (effective 2022-12-30).

“On December 30, 2022, the Company entered into a Promissory Note Amendment (the “Investor Amendment”), to the Promissory Notes entered into September 21, 2022, with Jonathan Lutz, an accredited investor.”

Odyssey Health, Inc. amended Amendment No. 4 to the Convertible Promissory Note with LGH Investments, LLC (effective 2022-12-29).

“On December 29, 2022, Odyssey Health, Inc., f/k/a Odyssey Group International, Inc. (the “Company”), entered into Amendment No. 4 to the Convertible Promissory Note (the “Amendment”) to the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC (“LGH”).”

Odyssey Health, Inc. entered into Option to Purchase Intellectual Property Agreement with Prevacus, Inc. (effective 2022-11-21).

“On November 21, 2022, Odyssey Health, Inc. (the “Company” “Odyssey”) entered into an Option to Purchase Intellectual Property Agreement (the “Option Agreement”) with Prevacus, Inc. (“Prevacus”).”

Greg Gironda was appointed as Chief Operations Officer at Odyssey Health, Inc..

“On November 1, 2022, the Company and Mr. Gironda entered into an employment agreement (the “Agreement”) for a one (1) year term as Chief Operations Officer.”

Erik Emerson was appointed as Chief Commercial Officer at Odyssey Health, Inc..

“On November 1, 2022, the Company and Mr. Emerson entered into an employment agreement (the “Agreement”) for a one (1) year term as Chief Commercial Officer.”